Key Highlights
- Tiziana Life Sciences (Nasdaq: TLSA) signed a Memorandum of Understanding with KAIMRC and the Foundation for Neurologic Diseases.
- The agreement will test intranasal foralumab combined with anti-CD20 therapy in non-responding RRMS patients.
- A separate Phase 2 trial readout for non-active secondary progressive MS remains on track for October 2026.
- The MOU broadens Tiziana's multiple sclerosis pipeline beyond its current blinded Phase 2 study.
New Combination Approach in Non-Responding RRMS
Tiziana Life Sciences (Nasdaq: TLSA) has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases. The agreement will support a clinical trial testing intranasal foralumab in combination with anti-CD20 therapy in patients with relapsing-remitting multiple sclerosis who have not responded to existing treatments.
na-SPMS Readout Still on Track
The new collaboration sits alongside Tiziana Life Sciences' (Nasdaq: TLSA) ongoing, blinded Phase 2 trial in non-active secondary progressive multiple sclerosis, for which a data readout remains on track for October 2026. Together, the two programs broaden the company's multiple sclerosis pipeline across different patient populations and treatment approaches.
Pipeline Expansion Continues
By pairing foralumab, delivered intranasally, with an established anti-CD20 therapy, Tiziana Life Sciences (Nasdaq: TLSA) is targeting a subset of RRMS patients for whom current treatment Options have proven insufficient, extending its multiple sclerosis Franchise beyond the na-SPMS indication already in late-stage testing.
What does the new MOU cover?
Testing intranasal foralumab combined with anti-CD20 therapy in non-responding RRMS patients, in Partnership with KAIMRC and the Foundation for Neurologic Diseases.
What is the status of the na-SPMS trial?
A Phase 2 trial readout for non-active secondary progressive MS remains on track for October 2026.
What is foralumab?
An intranasally delivered therapy from Tiziana Life Sciences being evaluated across multiple multiple sclerosis patient populations.






Please wait processing your request...